Acrivon Therapeutics, Inc. (ACRV): Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1…

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Regulation FD Disclosure. Safety, dose optimization, and early Phase 1/2 clinical results in AP3-predicted tumors for ACR-2316, a first-in-class WEE1/PKMYT1 inhibitor Timothy A. Yap1, Mohamad A. Salkeni2, Neel Gandhi3, Gerald Falchook4, David Sommerhalder5, Benedito A. Carneiro6, Judy Wang7, Monica Mita8,

Event · Clinical / regulatory
Product
ACR-2316
Milestone
topline data
Indication
advanced solid tumors

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 20, 2026, 9:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 9:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ACRV
Bullish
medium confidence
Mentioned
$ACRV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$ACRVBullishMed
01

Why it matters

The filing provides early safety and dose-escalation context (including hematologic AEs and absence of Grade 5 events) that can affect near-term positioning in ACRV as investors assess whether the program can advance to dose expansion and later efficacy readouts.

02

Market read

Traders can reassess the probability of continued dose escalation and progression based on early tolerability and the absence of severe non-hematologic toxicity in the disclosed cohort.

03

What to watch

The data are non-QC’d with a specific cut-off, and the open-label, dose-escalation context increases the chance of later revisions or different tolerability at expansion doses.

Relevance 7/10Novelty 7/10Timing: after-hours filing on 2026-11-20

Background

The 8-K is a Regulation FD disclosure for Acrivon’s first-in-human Phase 1/2 study of oral ACR-2316, a WEE1/PKMYT1 inhibitor designed using AP3 predictive precision proteomics.

Company-level read

Ticker impact

$ACRVBullishMedium confidence
Context

Acrivon filed an 8-K with Regulation FD disclosures describing early Phase 1/2 safety and dose-escalation results for ACR-2316 in AP3-predicted tumors.

Expected impact

Likely modest upside bias as traders price in progress on a first-in-class WEE1/PKMYT1 program, tempered by early Phase 1/2 uncertainty.

Evidence & confidence

The disclosure includes safety (no Grade 5 AEs, no non-hematologic DLTs) and trial design details, but it is not a pivotal efficacy readout and is non-QC’d with a specific data cut-off.

Market effects

Adds incremental validation for WEE1/PKMYT1 checkpoint inhibition and AP3 proteomics-driven patient selection, which can influence sentiment across cell-cycle targeted oncology peers.

Limited direct regional impact; primarily affects US small/mid-cap biotech sentiment.

Low global spillover beyond oncology clinical-trial sentiment.

Counterpoint

Safety signals may not translate into durable efficacy; without confirmed ORR/DOR in this excerpt, the market may fade the initial enthusiasm.

Key entities

  • Acrivon Therapeutics, Inc.

    Issuer filing the 8-K and disclosing early Phase 1/2 results for ACR-2316.

  • ACR-2316

    Oral, once-daily WEE1/PKMYT1 inhibitor designed to activate CDK1, CDK2, and PLK1.

  • AP3 (Acrivon Predictive Precision Proteomics)

    Proteomics-based approach used to identify AP3-predicted tumor types for enrollment.

Related articles

$ACRVMed

Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights

Acrivon Therapeutics, Inc. (ACRV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach AI-driven AP3 platform was us

$ACRVMedAI 8/10

Acrivon Therapeutics Highlights Phase 2-Ready ACR-525 and Preclinical EoE Programs

Acrivon Therapeutics presented its immunology and inflammation programs, including the Phase 2-ready ACR-525, a selective JAK1 inhibitor, and a preclinical PKCθ inhibitor program, at an R&D event. The company highlighted EoE's growing patient population and treatment gaps as rationale for ACR-525's development, citing favorable early clinical data and safety profile. The presentation is available on the company's investor website.

$ACRVMedAI 8/10

Acrivon to present cancer drug trial data at November symposium

Acrivon Therapeutics (ACRV) will present Phase 1/2 trial data for ACR-2316 at a cancer symposium in November. The study showed clinical activity in endometrial and lung cancers, with one patient achieving complete response. The trial has progressed to dose expansion, including pancreatic cancer patients. ACRV uses its AP3 platform to predict patient responses.

$ACRVMedAI 8/10

Acrivon advances CDK11 inhibitor for AML, targets 2027 IND filing

Acrivon Therapeutics (ACRV) announced the advancement of ACR-7280, an oral CDK11 inhibitor, as its next development candidate. The company plans to file an IND application for the drug with the FDA in the first half of 2027. ACR-7280 showed complete tumor regression in AML xenograft models and potential in combination therapies. Acrivon's lead program, ACR-368, is in a Phase 2 trial for endometrial cancer.